Dehydroepiandrosterone (DHEA) and the menopause: An update

Menopause International

Volumn 13, Issue 2, 2007, Pages 75-78

  Raven, P W ^a   Hinson, J P ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

BREAST CANCER; CARDIOVASCULAR DISEASE; DEHYDROEPIANDROSTERONE (SULFATE); MENOPAUSE; OSTEOPOROSIS

Indexed keywords

IMMUNOLOGICAL ADJUVANT; PRASTERONE; GLUCOCORTICOID;

BREAST TUMOR; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; DRUG EFFECT; FEMALE; HUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; WOMEN'S HEALTH; ALZHEIMER DISEASE; ANDROGEN BLOOD LEVEL; ANDROGEN THERAPY; BONE DENSITY; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DEPRESSION; DIET SUPPLEMENTATION; DRUG MEGADOSE; DRUG WITHDRAWAL; FIBROMYALGIA; MENOPAUSE; NONHUMAN; OILY SKIN; RISK REDUCTION; SKIN DEFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; VASOMOTOR DISORDER; WELLBEING;

ADJUVANTS, IMMUNOLOGIC; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; DEHYDROEPIANDROSTERONE; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 36049031865     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1258/175404507780796370     Document Type: Review

References (37)

1. Raven PW, Hinson JP. DHEA and the menopause: a new approach to HRT? J Br Menopause Soc 2001;7:175–80.
2. Labrie F, Luu-The V, Belanger A, et al. Is dehydroepiandrosterone a hormone? J Endocrinol 2005;187:169–96.
3. Widstrom RL, Dillon JS. Is there a receptor for dehydroepiandrosterone and dehydroepiandrosterone sulphate? Semin Reprod Med 2004;22:289–98.
4. Charalampopoulos I, Alexaki VI, LAzaridis I, et al. G-protein associated, specific membrane binding sites mediate the neuroprotective effect of dehydroepiandrosterone. FASEB J 2006;20; 577–9.
5. Webb SJ, Geoghegan TE, Prough RA, Miller MKK. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev 2006;38:89–116.
6. Svec F, Porter JR. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Soc Exp Biol Med 1997;218:174–91.
7. Hinson JP, Raven PW. DHEA deficiency syndrome: a new term for old age? J Endocrinol 1999;163:1–5.
8. Bjornerem A, Straume B, Midtby M, et al. Endogenous sex hormones in relation to age, sex, lifestyle factors and chronic diseases in a general population: the Tromso study. J Clin Endocrinol Metab 2004;89:6039–47.
9. Cappola AR, Xue QL, Walston JD, et al. DHEAS levels and mortality in disabled older women: the Women's Health and Aging study. J Gerontol A Biol Sci Med Sci 2006;61:957–62.
10. Randolph JF, Sowers M, Bondarenko I, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 2005;90:6106–12.
11. Stomati M, Monteleone P, Casarosa E, et al. Six-month oral dehydroepiandrosterone supplementation in early and late menopause. Gynecol Endocrinol 2000;14:342–63.
12. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. New Engl J Med 1999;341:1013–20.
13. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone (DHEA) in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360–7.
14. Finckh, A, Berner IC, Aubry-Rozier B, So AK. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol 2005;32:1336–40.
15. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005;62:154–62.
16. Von Muhlen D, Laughlin GA, Kritz-Silverstein D, Barrett-Conner E. The dehydroepiandrosterone and wellness (DAWN) study: research design and methods. Contemp Clin Trials 2007;28:153–68.
17. Aziz A, Brannstrom M, Bergquist C, Silfverstolpe G. Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being. Fertil Steril 2005;83:1021–8.
18. Bell RJ, Donath S, Davison SL, Davis SR. Endogenous androgen levels and well-being: differences between premenopausal and postmenopausal women. Menopause 2006;13:65–71.
19. Lebrun CE, van der Schouw YT, de Jong FH, et al. Relations between body composition, functional and hormonal parameters and quality of life in healthy postmenopausal women. Maturitas 2006;55;82–92.
20. Wolkowitz OM, Kramer JH, Reus VI, et al. DHEA treatment of Alzheimer's disease: a randomised, double-blind placebocontrolled study. Neurology 2003;60:1071–6.
21. Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a twoweek physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997;82:2363–7.
22. Wolf OT, Kudielka BM, Hellhammer DH, et al. Opposing effects of DHEA replacement in elderly subjects on declarative memory and attention after exposure to a laboratory stressor. Psychoneuroendocrinology 1998;23;617–29.
23. Hirshman E, Merritt P, Wang CCL, et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Horm Behav 2004;45:144–55.
24. Villareal DT, Holloszy JO, Kohrt WN. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol 2000;53:561–8.
25. Labrie F, Diamond P, Cusan L, et al. Effect of 12 month dehydroepiandrosterone therapy on bone, vagina and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498–3505.
26. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge study to a sociobiomedical issue. Proc Natl Acad Sci 2000;97: 4379–84.
27. Villareal DT. Effects of dehydroepiandrosterone on bone mineral density: what implications for therapy? Treat Endocrinol 2002;1: 349–57.
28. Kocis P. Prasterone. Am J Health Syst Pharm 2006;63:2201–10.
29. Osmanagaoglu MA, Okumus B, Osmanagaoglu T, Bozkaya H. The relationship between serum dehydroepiandrosterone sulfate concentration and bone mineral density, lipids, and hormone replacement therapy in premenopausal and postmenopausal women. J Women's Health 2004;13:993–9.
30. Tok EC, Ertunc D, Oz U, et al. The effect of circulating androgens on bone mineral density in postmenopausal women. Maturitas 2004;48:235–42.
31. Garnero P, Sornay-Rendu E, Claustrat B, Delmas P. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526–36.
32. Genazzani AD, Stomati M, Strucchi C, et al. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late menopausal women. Fertil Steril 2001;76:241–8.
33. Christiansen JJ, Andersen NH, Sorensen KE, et al. Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalisation of androgen status. Clin Endocrinol 2007;66:426–33.
34. Silvestri A, Gambacciani M, Vitale C, et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas 2005;50:305–11.
35. Lasco A, Frisina N, Morabito N, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 2001;145:457–61.
36. Bell RJ, Davison SL, Papalia MA, et al. Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. Menopause 2007;11.
37. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005;12:1071–82.